WT1 expression increases with malignancy and indicates unfavourable outcome in astrocytoma.

Julian RauscherRudi BeschornerMidea GierkeSotirios BisdasChristian BraunFlorian H EbnerCornelia Brendle

Published in: Journal of clinical pathology (2014)

The significant WT1 expression differences between diffuse astrocytomas, oligoastrocytomas and oligodendrogliomas, which are also present in the Repository for Molecular Brain Neoplasia Data, National Cancer Institute (REMBRANDT, 2005, http://rembrandt.nci.nih.gov) gene database set, provide a rationale for use of WT1 as part of a routine immunohistochemistry panel.

Keyphrases

poor prognosis
binding protein
genome wide
high grade
electronic health record
long non coding rna
copy number
clinical practice
low grade
gene expression
single molecule
emergency department
multiple sclerosis
adverse drug
resting state
dna methylation
artificial intelligence
blood brain barrier